Verbatim response from ChatGPT
Short answer: probably not. Compounded “GLP‑1 drops” or home‑made tablets are unreliable and usually won’t give the same, proven benefit as FDA‑approved products. If you want an oral GLP‑1, use the approved prescription (Rybelsus). For stronger or more predictable effects, use an approved injectable (e.g., Ozempic/Wegovy, Victoza/Saxenda, Trulicity).
Why compounded drops/tablets are a poor choice
- GLP‑1 drugs are peptides that are destroyed in the stomach and have very low absorption unless formulated specifically. Approved oral semaglutide (Rybelsus) uses a patented absorption enhancer (SNAC) and specific dosing instructions to work. Compounded versions usually lack that technology.
- Sublingual/oral “drops” marketed by clinics or compounding pharmacies rarely have rigorous clinical testing. There’s little to no reliable evidence they achieve therapeutic blood levels.
- Compounded products have variable potency, stability and sterility. That raises risks of under‑dosing (no benefit), overdosing, contamination, or unexpected side effects.
- Regulatory and safety issues: compounding is not the same as an FDA approval process — safety, efficacy and manufacturing controls differ.
What does work (approved options)
- Rybelsus (oral semaglutide): the only FDA‑approved oral GLP‑1 receptor agonist. Proven in clinical trials for type 2 diabetes and has dosing guidance (take fasting, very small amount of water, wait ~30 min before eating).
- Injectable GLP‑1 receptor agonists: generally give greater and more consistent exposure and often more weight loss/GLP‑1 effect. Examples:
- Semaglutide injections: Ozempic (for diabetes), Wegovy (for weight loss at higher dose).
- Liraglutide: Victoza (diabetes), Saxenda (weight).
- Dulaglutide: Trulicity.
- Exenatide: Byetta/Bydureon. These are prescription, manufactured under strict controls, and supported by clinical trial data.
Safety and practical points
- Side effects — nausea, vomiting, diarrhea, reduced appetite; watch for signs of pancreatitis. If you’re on insulin or sulfonylureas, hypoglycemia risk can increase.
- Contraindications — personal or family history of medullary thyroid carcinoma or MEN2 are important to tell your prescriber.
- Cost/access — if cost is why you’re considering a compounded product, check manufacturer savings cards, copay programs, or discuss alternatives with your clinician; sometimes Rybelsus or injectables have assistance programs.
Bottom line / recommendation
- Don’t rely on compounded GLP‑1 drops/tablets — they’re unproven and can be risky.
- If you want an oral option, ask your clinician about Rybelsus (approved oral semaglutide).
- If you need the most effective option for weight loss or glycemic control, discuss an approved injection (Wegovy/Ozempic, Victoza/Saxenda, Trulicity) with your prescriber.
- Always get prescription GLP‑1 drugs from a licensed pharmacy and follow a clinician’s monitoring plan.
If you want, tell me why you’re considering a compounded product (cost, needle phobia, availability) and I can suggest specific steps or programs to make an approved option more accessible.